Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.25)
# 450
Out of 5,111 analysts
502
Total ratings
48.69%
Success rate
17.03%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $23 → $26 | $21.90 | +18.72% | 22 | Dec 12, 2025 | |
| RZLT Rezolute | Maintains: Buy | $14 → $5 | $1.63 | +206.75% | 19 | Dec 12, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $34 → $40 | $29.60 | +35.14% | 3 | Dec 9, 2025 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $340 | $276.40 | +23.01% | 30 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $30 → $11 | $11.28 | -2.48% | 16 | Dec 3, 2025 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $2.28 | +426.32% | 18 | Dec 2, 2025 | |
| PCRX Pacira BioSciences | Assumes: Buy | $38 | $26.68 | +42.43% | 3 | Nov 17, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $17.77 | +12.55% | 16 | Nov 11, 2025 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $5 → $4 | $4.09 | -2.08% | 15 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $24.56 | +83.22% | 27 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $774 → $915 | $850.95 | +7.53% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.39 | +569.46% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $94.79 | -15.60% | 35 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1 | $2.17 | -53.92% | 18 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $28.17 | +63.29% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $26.00 | +34.62% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.98 | +134.90% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $7.14 | +180.11% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $92.00 | +28.26% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $49.32 | +64.23% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $43.60 | +21.56% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.39 | +403.60% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $33.03 | +2.94% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $28.95 | -34.37% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.96 | +818.37% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.86 | +41,566.67% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.70 | +488.24% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $184.37 | -1.29% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.70 | +143.51% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $40.67 | -55.74% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $30.13 | -73.45% | 7 | Jun 11, 2019 |
Roivant Sciences
Dec 12, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $21.90
Upside: +18.72%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $1.63
Upside: +206.75%
Rapport Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $29.60
Upside: +35.14%
Praxis Precision Medicines
Dec 8, 2025
Reiterates: Buy
Price Target: $340
Current: $276.40
Upside: +23.01%
Biohaven
Dec 3, 2025
Downgrades: Neutral
Price Target: $30 → $11
Current: $11.28
Upside: -2.48%
Daré Bioscience
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $2.28
Upside: +426.32%
Pacira BioSciences
Nov 17, 2025
Assumes: Buy
Price Target: $38
Current: $26.68
Upside: +42.43%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $17.77
Upside: +12.55%
Minerva Neurosciences
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $4.09
Upside: -2.08%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $24.56
Upside: +83.22%
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $850.95
Upside: +7.53%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.39
Upside: +569.46%
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $94.79
Upside: -15.60%
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $2.17
Upside: -53.92%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $28.17
Upside: +63.29%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $26.00
Upside: +34.62%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.98
Upside: +134.90%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $7.14
Upside: +180.11%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $92.00
Upside: +28.26%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $49.32
Upside: +64.23%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $43.60
Upside: +21.56%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.39
Upside: +403.60%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $33.03
Upside: +2.94%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $28.95
Upside: -34.37%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.96
Upside: +818.37%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.86
Upside: +41,566.67%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.70
Upside: +488.24%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $184.37
Upside: -1.29%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.70
Upside: +143.51%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $40.67
Upside: -55.74%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $30.13
Upside: -73.45%